



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 6, 2022

Hamza Suria
Chief Executive Officer
ANAPTYSBIO, INC
10770 Wateridge Circle, Suite 210
San Diego, CA 92121

Re: ANAPTYSBIO, INC
Registration Statement on Form S-3
Filed December 30, 2021
File No. 333-261953

Dear Hamza Suria:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Michael Davis at 202-551-4385 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Ryan Mittenness